Anti-canine CD20 antibody
Isolated canine antibodies with specific CDR sequences, produced in transgenic rodents, address the lack of effective therapies for canine CD20 by providing targeted treatment for B-cell lymphoma and other conditions with enhanced efficacy and reduced immunogenicity.
JP7873686B2Inactive Publication Date: 2026-06-12ZOETIS SERVICES UK LTD
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- ZOETIS SERVICES UK LTD
- Filing Date
- 2022-06-17
- Publication Date
- 2026-06-12
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Technical Problem
There is a need for effective therapies targeting canine CD20, as existing human antibodies like rituximab are not currently in common clinical use for treating canine lymphoma and other B-cell mediated conditions.
Method used
Development of isolated canine antibodies or their antigen-binding moieties that specifically bind to canine CD20, utilizing specific CDR sequences and variable regions, produced in transgenic rodents to minimize immunogenicity and ensure optimal affinity and efficacy.
Benefits of technology
The canine antibodies effectively target CD20-expressing cells, offering potential therapeutic benefits for B-cell lymphoma and other B-cell mediated conditions in dogs, with reduced risk of immunogenicity and improved affinity.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 0007873686000042 
Figure 0007873686000043 
Figure 0007873686000044
Abstract
The present disclosure relates to antibodies and antigen-binding portions thereof that bind to canine CD20. The present disclosure also relates to compositions and methods for the treatment of B-cell mediated conditions in canine subjects.
Need to check novelty before this filing date? Find Prior Art